文献速递乳腺癌胸部肿瘤消化系统肿瘤

精准肿瘤学时代随机临床试验的演变

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
PubMed 文献 · JAMA Oncol · 2021-01-01

该回顾性队列研究分析了2010至2020年发表于7大期刊的298项乳腺癌、结直肠癌和非小细胞肺癌系统治疗随机临床试验,并与1995-2004年和2005-2009年的数据比较。结果显示无进展生存期作为主要终点从0%增至42%,工业资助从57%增至89%,阳性试验中总生存和无进展生存中位改善分别为3.4和2.9个月。

要点

  • 无进展生存期已成为最常见主要终点,占比从0%升至42%。
  • 89%的随机临床试验由工业界资助,较此前57%和78%显著增加。
  • 阳性试验中总生存中位改善仅3.4个月,无进展生存2.9个月。

核心结论

  • 当代肿瘤随机临床试验主要采用替代终点且几乎完全由制药工业资助。
  • 医学写作人员的参与增加值得关注。
  • 肿瘤学界需考虑研究终点和目标效应量对患者的实际获益程度。

研究设计与样本

  • 回顾性队列研究,纳入2010至2020年发表于7大期刊的298项系统治疗随机临床试验。
  • 覆盖乳腺癌132项(44%)、非小细胞肺癌111项(37%)、结直肠癌55项(19%)。
  • 与1995-2004年和2005-2009年发表的随机临床试验数据进行比较。

主要发现

  • 实验治疗包括分子抑制剂171/298(57%)、细胞毒药物83/298(28%)、激素15/298(5%)、免疫治疗24/298(8%)。
  • 主要终点为无进展生存期的比例从0%(0/167)增至18%(25/137)再增至42%(125/298),P < .001。
  • 工业界资助比例从57%(95/167)、78%(107/137)增至89%(265/298),P < .001。

临床怎么用

  • 解读随机临床试验结果时需关注主要终点是否为替代终点及其临床意义。
  • 应审视工业资助对研究设计、终点选择和报告的影响。
  • 评估阳性试验的绝对获益(如中位改善月数)以判断临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The randomized clinical trial (RCT) in oncology has evolved since its widespread adoption in the 1970s. In recent years, concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS), and marginal effect sizes. OBJECTIVE: To describe contemporary trends in oncology RCTs and compare these findings with earlier eras of RCT design and output. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of systemic therapy RCTs in breast, colorectal, and non-small cell lung cancer published in 7 major journals between 2010 and 2020. This strategy replicates prior work and allows for comparison of trends with RCTs published between 1995 to 2004 and 2005 to 2009. MAIN OUTCOMES AND MEASURES: Data on RCT design, funding, results, and reporting were extracted from the published RCT report. Findings from the current period (2010-2020) were compared with data from RCTs published from 1995 to 2004 and 2005 to 2009. Descriptive and bivariate statistics were used to analyze temporal trends. RESULTS: The cohort included 298 RCTs (132 [44%] breast, 111 [37%] non-small cell lung cancer, 55 [19%] colorectal cancer). Experimental treatment included molecular inhibitor (171 of 298 [57%]), cytotoxic (83 of 298 [28%]), hormone (15 of 298 [5%]), and immune (24 of 298 [8%]) therapies. Sixty-nine percent (206 of 298) of RCTs were of palliative intent. The most common primary end point is now PFS; this has increased substantially over time (from 0% [0 of 167] to 18% [25 of 137] to 42% [125 of 298]; P < .001). Of 298 RCTs, 265 (89%) are now funded by industry (previously 95 of 167 [57%] and 107 of 137 [78%]; P < .001). Fifty-eight percent (173 of 298) of trials met their primary end point. Among positive trials, median improvement in overall survival and PFS was 3.4 and 2.9 months, respectively. More than one-third (117 of 298 [39%]) of reports used a professional medical writer; this increased substantially during the study period (from 3 of 27 [11%] in 2010 to 12 of 18 [67%] in 2020; P < .001). CONCLUSIONS AND RELEVANCE: This cohort study suggests that contemporary oncology RCTs now largely measure putative surrogate end points and are almost exclusively funded by the pharmaceutical industry. The increasing role of medical writers warrants attention. To demonstrate that new cancer treatments are high value, the oncology community needs to consider the extent to which study end points and target effect size provide meaningful benefit to patients.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Del Paggio JC, Berry JS, Hopman WM, et al. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol. 2021. PMID: 33764385. doi:10.1001/jamaoncol.2021.0379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。